-
【GE CHENG News】CNIPA and DPMA extend PPH pilot program
2025-05-08The China National Intellectual Property Administration (CNIPA) and the German Patent and Trade Mark Office (DPMA) have jointly decided to extend their Patent Prosecution Highway (PPH) pilot program for another three years from January 23, 2024 to January 22, 2027. The established Procedures to file -
【GE CHENG News】Added value of China’s copyright industry in 2022 accounting for 7.41% of GDP
2025-05-08Recently, the Chinese Academy of Press and Publication (CAPP), under the guidance of the National Copyright Administration, completed a research report on the Economic Contribution of Chinas Copyright Industry in 2022. The added value of China’s copyright industry reached 8.97 trillion yuan in 2022 -
【GE CHENG News】China becomes the first country to hold over 4M domestic valid invention patents
2025-05-08China owned 4.015 million domestic valid invention patents by the end of 2023, up 22.4 percent year-on-year, becoming the first country in the world to hold more than 4 million domestic valid invention patents.It took 31 years for the effective number of invention patents in China (excluding Hong Ko -
【GE CHENG News】CAICT: China tops in AI patent applications with a cumulative 1.29 million accounting for 64% of the world's total
2025-05-08Recently, the China Academy of Information and Communications Technology officially released the "White Paper on Global Digital Economy (2023)". According to the white paper, the artificial intelligence industry is ushering in rapid development, with intensifying innovation and application, and the -
【GE CHENG News】Sino Biopharmaceutical successfully applies for the patent of Sirolimus Tablets and achieves its first generic launch
2025-05-08Sino Biopharmaceuticals announced that Sirolimus Tablets (trademark name: Qingweishi) developed by it have received marketing approval from the National Medical Products Administration, which is the first product, since China implemented the early resolution mechanism for drug patent disputes (drug